论文部分内容阅读
阿司匹林(aspirinl)与双嘧达莫(dipyridamole)均为老药新用的典型代表,尤其是阿司匹林在众多的抗血小板药中仍然应用最广。目前全世界每年生产45 000吨阿司匹林。拜尔公司1996年向全世界70个国家的销售量高达110亿片。然而阿司匹林作用较窄,只能对抗花生四烯酸代谢途径中依赖环氧化酶的血小板激活,而且阿司匹林虽无严重毒性。但不良反应较多。如果根据患者的具体情况,慎重地调整剂量或将小剂量阿司匹林与双嘧达莫联用可能将取得更为理想的抗栓效果。双嘧达莫不仅能抑制磷酸二酯酶,使cAMP降解减少,而且能激活腺苷环化酶,使cAMP生成增多,从另一角度对抗血小板激活,延长血小板的生存时间。若单独应用,疗效小及与阿司匹林合用。
Aspirin (aspirinl) and dipyridamole (dipyridamole) are typical new representatives of old drugs, especially aspirin is still the most widely used in many antiplatelet drugs. Currently, 45,000 tons of aspirin are produced annually in the world. Bayer sold up to 11 billion pieces in 70 countries in 1996. However, aspirin has a narrower effect and can only counteract cyclooxygenase-dependent platelet activation in the arachidonic acid metabolic pathway, although aspirin is not very toxic. But more adverse reactions. If the patient’s specific circumstances, carefully adjust the dose or small doses of aspirin and dipyridamole combination may be the ideal antithrombotic effect. Dipyridamole can not only inhibit phosphodiesterase, cAMP degradation decreased, and can activate adenylyl cyclase, cAMP generation increased, from another angle against platelet activation, prolonging the survival time of platelets. If used alone, small effect and with aspirin.